scAAV9/AGA
2013-AGU
Phase 2 gene_therapy active
Quick answer
scAAV9/AGA for Aspartylglucosaminuria is a Phase 2 program (gene_therapy) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Aspartylglucosaminuria
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- active